Abstract: RESULTS: During 3TC and ADV therapy, 11 patients had rtM204V/I mutations, 2 had rtA181V/T or rtN236T, 7 had both and 2 had no 3TC- or ADV-related mutations.
Abstract: Relative abundances of rtM204V/I mutations in total viral populations gradually increased under ETV rescue, whereas those with rtA181V/T and rtN236T mutations decreased.
New approaches in the management of chronic hepatitis B: role of tenofovir.
Method: In vitro studies, however, show that both rtN236T and rtA181V/T HBV mutants remain sensitive to TDF, and are only associated with small decreases in susceptibility.
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
Abstract: Five (12%) patients developed ADV-resistant mutations: rtN236T in four cases and one case with an rtV207L change, which has not been previously reported.
[Kinetics of HBV mutants conferring adefovir resistance (rtn236t) and a method to detect them rapidly].
Abstract: A novel PCR-RFLP assay based on restriction enzyme HpaI or DraI for on the detection of rtN236T mutant was established, which detected 10% minor strains with 100% specificity.
Abstract: CONCLUSIONS: A rapid and easy method was established to detect rtN236T mutants.
Abstract: In one patient after stopping the adefovir therapy, 3 months later a wild type virus re-took again the mutant one (rtN236T); in one patient who developed a rt236T mutant after 132 weeks of adefovir treatment, a novel mutant (rtN236V) appeared and then became the dominant one while adefovir treatment continued.
Abstract: Mutants (rt PMID: 18331765
2008
Journal of hepatology
Abstract: Interestingly, the association of rtA181T with rtN236T on one clinical isolate genome increased the resistance to these three drugs.
Abstract: RESULTS: Clonal analysis revealed the co-localization on the same HBV genome of rtA181T/V with rtN236T, but not with rtM204V/I mutations following lamivudine, adefovir or lamivudine+adefovir breakthrough.
Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B.
Abstract: No subject developed an ADV-associated mutation that has been linked to HBV DNA rebound (that is, mutations rtN236T or rtA181V).
Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
Abstract: In the remaining 129 patients, the rtM204 mutants were identified at baseline, and two (1.6%) of the 129 patients developed new ADV-resistant mutants; one was rtA181S and another was rtA181T plus rtN236T mutation.
HBV mutation literature information.
PMID: 
2009
Alimentary pharmacology & therapeutics
Browser Board
Co-occurred Entities
Filtrator
ViMRT